Scholar Rock shares jump 300% after rare disease drug scores trial win
Adds analyst comments in paragraphs 6 and 7, similar drugs in paragraphs 5 and 8, updates shares
By Christy Santhosh
Oct 7 (Reuters) -Scholar Rock's SRRK.O experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading.
The treatment, apitegromab, was statistically significant in improving motor function measures such as standing and crawling, compared to a placebo, in individuals suffering from the rare disease.
SMA is the leading genetic cause of infant deaths and affects about 1 in 10,000 people, according to U.S. government data. It prevents the body from producing a protein necessary for neuromuscular development and leaves children too weak to walk, talk and swallow.
Apitegromab works to improve muscle strength and development by blocking the effects of myostatin, a protein which inhibits muscle growth.
There are currently three treatments for SMA approved by the U.S. Food and Drug Administration: Biogen's BIIB.O Spinraza, Novartis's NOVN.S gene therapy, Zolgensma, and Roche ROG.S and PTC Therapeutics' PTCT.O oral drug, Evrysdi. None of these targets muscle development.
Wall Street analysts said they expected apitegromab to gain FDA approval, despite a higher dose falling below efficacy expectations in the trial.
The drug had hit a "bullseye", said Truist analyst Srikripa Devarakonda, who now forecasts $1.2 billion in peak sales of the drug in SMA patients, from $750 million previously.
A rival drug from Biohaven BHVN.N, also focusing on muscle retention, is in late-stage development for the disease.
Scholar Rock expects to file for FDA approval in the first quarter of 2025.
The latest results could bode well for separate trials testing the drug's ability to preserve lean muscle mass in obese patients on GLP-1 weight-loss drugs such as Eli Lilly's LLY.N Zepbound, analysts said.
Scholar Rock is expected to report data from the obesity studies in the second quarter of 2025.
Its shares were trading at $30.38. Until Friday's close of $7.42, the stock had lost 60.5% of its value this year.
Reporting by Christy Santhosh in Bengaluru; Editing by Pooja Desai
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
